KRYS
Krystal Biotech Inc
341.80$
-2.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2.6% | 10.4% | 5.3% | 8.5% | 8.0% | 5.4% | 5.7% | 7.5% | 5.8% | 10.2% | 5.4% | 5.4% | 6.7% | |
| 97.4% | 89.6% | 94.7% | 91.5% | 92.0% | 94.6% | 94.3% | 92.5% | 94.2% | 89.8% | 94.6% | 94.6% | 93.3% | |
| 124.2% | 27.0% | 24.2% | 22.2% | 16.1% | 14.8% | 16.2% | 15.0% | 13.5% | 15.1% | 13.2% | 12.2% | 13.4% | |
| 277.0% | 174.7% | 57.6% | 39.3% | 34.2% | 34.3% | 37.1% | 36.6% | 38.4% | 38.7% | 35.2% | 33.4% | 36.3% | |
| 401.2% | 82.2% | 109.4% | 79.3% | 65.3% | 49.2% | 53.3% | 51.6% | 51.9% | 48.3% | 48.4% | 45.6% | 48.4% | |
| -303.8% | 7.4% | -14.8% | 12.2% | 26.8% | 45.4% | 41.0% | 40.9% | 42.3% | 41.5% | 46.1% | 49.0% | 44.9% | |
| – | 59.3% | – | – | – | – | – | – | – | – | – | – | – | |
| 943.7% | 25.3% | 2.1% | 22.8% | 35.5% | 53.3% | 49.4% | 48.7% | 49.0% | 47.7% | 52.8% | 55.4% | 51.4% | |
| -9.7% | 4.7% | 10.8% | 0.7% | 3.1% | 3.4% | 8.9% | 8.8% | -32.1% | -0.3% | 4.7% | 9.5% | -3.4% | |
| 943.7% | 20.6% | 2.1% | 22.2% | 32.4% | 49.9% | 40.5% | 39.9% | 81.2% | 48.0% | 48.1% | 45.9% | 54.8% | |
| 959.7% | 28.9% | 16.4% | 32.8% | 43.5% | 55.0% | 51.3% | 50.3% | 50.7% | 37.0% | 54.3% | 55.4% | 49.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.